Phylogica Surges On Early CPP Cancer Results
This article was originally published in PharmAsia News
Executive Summary
Phylogica is continuing its strong financial year, with the company’s shares surging after it announced that a pilot study for its cell-penetrating peptides (CPPs) showed these were able to kill drug-resistant breast cancer cells in vivo, when linked with the cancer drug Omomyc.